Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

Business Leaders

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors 
HomeAll NewsMost read newsBusiness Leaders Biography
Portrait de Merdad Parsey
Age : 57
Public asset : 1,093,877 USD
Country of residence : Unknown
Linked companies : Gilead Sciences, Inc. - Arcus Biosciences, Inc.

Biography of Merdad Parsey 
Dr. Merdad V. Parsey is an Independent Director at Arcus Biosciences, Inc. and a Chief Medical Officer at Gilead Sciences, Inc. He is on the Board of Directors at Arcus Biosciences, Inc. and Sagimet Biosciences, Inc. Dr. Parsey was previously employed as a Senior Medical Director by Regeneron Pharmaceuticals, Inc., a Senior Director-Medical Group by Genentech, Inc., an Associate Medical Director by Merck & Co., Inc., a Director-Critical Care Medicine by New York University School of Medicine, a Member by Roche Group, and a Senior Medical Director by Sunovion Pharmaceuticals, Inc. He received his doctorate degree from the University of Maryland.


Current positions of Merdad Parsey 
Holdings of Merdad Parsey 
Merdad Parsey : Personal Network 
Most Read News 
11/23ELON MUSK : Tesla's Musk exercises more options, sells shares worth $1.05 billion
RE
12/05MUKESH AMBANI : Indian salesmen threaten supply disruptions in protest against Reliance
RE
11/30JACK DORSEY : Jack Dorsey chases crypto, fintech dream post Twitter
RE
11/24JAMIE DIMON : Jamie Dimon jokes that JPMorgan will outlast China's Communist Party
RE
12/01JACK DORSEY : Dorsey-led Square rebrands to Block in nod to blockchain
RE
12/03CATHIE WOOD : Cathie Wood's ARK Innovation fund hits 13-month low in tech selloff
RE
11/26ELON MUSK : Tesla decides against state aid for German battery plant as Musk opposes subsidies
RE
12/02ELON MUSK : Musk exercises more options, sells Tesla shares worth $1.01 billion
RE
11/23ERIK NORDSTROM : Nordstrom warns of supply shortages as holiday season approaches, shares plunge
RE
12/02TILMAN FERTITTA : FAST Acquisition refuses to terminate SPAC merger with Fertitta Entertainment
RE
More news


© 2021 People and Ownership :   
Merdad Parsey : Connections 


Latest news about Merdad Parsey 
10/18Gilead Says FDA Approves Expanded Indication of Biktarvy for Treatment of HIV-1 in Pediatric Populations
DJ
06/28Gilead Submits NDA for Lenacapavir to U.S. FDA
DJ
05/21Inside the race to find a COVID-19 treatment pill
RE
05/21Inside the race to find a COVID-19 treatment pill
RE
03/25GILEAD SCIENCES : Gets EU Approval to Bring Breast-Cancer Drug to Market
DJ
03/12INSIDER TRENDS : Insider at Gilead Sciences Gets Share Award, Exercises Derivative Security, Makes Tax Sale with Portion
MT
02/04Gilead forecasts 2021 growth, strong remdesivir COVID-19 sales
RE
More news